| Old Articles: <Older 5171-5180 Newer> |
|---|
 |
The Motley Fool
October 14, 2008
Brian Orelli |
Johnson & Johnson, Heal Thyself When your brother falls, you've got to pick up the pace.   |
The Motley Fool
October 13, 2008
Brian Orelli |
Foolish Forecast: J&J's Diversity Counts Views you can use to get clues on tomorrow's news |
The Motley Fool
October 13, 2008
Brian Orelli |
Too Little Too Late for Boston Scientific The company gets new stent approved, but it should have happened earlier. |
The Motley Fool
October 9, 2008
Brian Orelli |
When Science, Marketing, and Investing Collide How a pharmaceutical tries to sell more drugs can provide clues about its management. |
The Motley Fool
October 8, 2008
Brian Orelli |
Lilly Gets Off Easy The company settles marketing issues over Zyprexa with 32 states. |
The Motley Fool
October 8, 2008
Brian Orelli |
Pfizer Rearranges the Deck Chairs A reorganization without any job cuts isn't going to make the Lipitor problem go away. |
The Motley Fool
October 7, 2008
Brian Orelli |
Will a Better Drug Sell Better? Positive trial data isn't enough to significantly boost Johnson & Johnson's Remicade. |
The Motley Fool
October 7, 2008
Brian Orelli |
Eli Lilly's Risky Gamble Eli Lilly is desperate, and the high acquisition price of ImClone shows it. |
The Motley Fool
October 7, 2008
Brian Orelli |
Results IMPACT Volatility at Dendreon Dendreon almost hits both a 52-week high and a 52-week low on the day it releases results. |
The Motley Fool
October 6, 2008
Brian Orelli |
Cardinal Atones for Its Sins The drugmaker gets its licenses to distribute controlled substances reinstated. |
| <Older 5171-5180 Newer> Return to current articles. |
